You and Your Dermatology Colleagues Are Invited to Attend
A Dermatology Milestone Symposium

Novel Treatment Strategies and the Trial-Based Rationale for
PD-1 TARGETING THERAPY in
ADVANCED and METASTATIC
CUTANEOUS SQUAMOUS CELL
CARCINOMA (CSCC)

Focus on the Pathoimmunobiology, Clinical Trials, Translational and Immunotherapeutic
Implications of PD-1 Checkpoint Inhibition in Advanced, Unresectable, and Metastatic Skin Cancers

Save the Time and Date: Friday, March 1, 2019
Time: 6:30 PM – 9:00 PM | Program Registration and Dinner: 6:30 PM – 7:00 PM
Clinical Program: 7:00 PM – 9:00 PM
City: Washington, DC | Location: Marriott Marquis Washington DC | Address: 901 Massachusetts Avenue NW
Conference Room: Liberty Ballroom M/N/O/P

REGISTER NOW: www.reg-CSCC.com

Supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals
This program is independent and is not part of the official AAD Annual Meeting, as planned by its Scientific Assembly Committee
Novel treatment strategies and the trial-based rationale for
PD-1 THERAPY in ADVANCED AND METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

Focus on the pathoimmunobiology, clinical trials, translational and immunotherapeutic implications of PD-1 checkpoint inhibition in advanced, unresectable, and metastatic skin cancers.

**CLINICAL PROGRAM AGENDA**

**6:30 PM – 7:00 PM**
Program Registration, Buffet Dinner and Pre-Program Learner Assessments

**7:00 PM – 7:20 PM**
Welcome and Program Overview
Clinical burden and unmet therapeutic needs in patients with advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

How effective is the current management arsenal? What is the latest trial-based evidence for efficacy and safety of immune checkpoint inhibition for CSCC?

Todd E. Schlesinger, MD, FAAD – Program Chair
Director, Dermatology and Laser Center of Charleston | Clinical Research Center of the Carolinas | Clinical Instructor, University at Buffalo Department of Dermatology | Assistant Clinical Professor, Medical University of South Carolina Department of Family Medicine | Clinical Preceptor, Medical University of South Carolina College of Health Professions | Charleston, SC

**7:20 PM – 7:40 PM**
The pathoimmunobiology and translational implications of targeting the PD-1 checkpoint in metastatic cutaneous squamous cell carcinoma (CSCC)

PD-1 and PD-L1 expression in the CSCC microenvironment and their role as biomarkers of drug responsiveness in CSCC

Sherrif F. Ibrahim, MD, PhD
Associate Professor, Dermatology | Division of Dermatologic Surgery | Wilmot Cancer Center | University of Rochester | Rochester, NY

**7:40 PM – 8:00 PM**
Landmark trial-based evidence supporting the efficacy, patient outcomes, and safety of PD-1 checkpoint inhibition in advanced and metastatic CSCC

What do the trials teach us and what are the immediate translational implications for PD-1 targeting immunotherapy in CSCC?

Chrysalyne D. Schmitts, MD
Professor of Dermatology | Harvard Medical School | Brigham and Women’s Hospital | Department of Dermatology | Boston, MA

**8:00 PM – 8:30 PM**
Interactive case management and dialogue sessions focused on identifying real-world patients with CSCC who are appropriate candidates for PD-1 checkpoint inhibition

Faculty moderate interactive case studies with audience response system (ARS)

**8:30 PM – 8:40 PM**
Chair vision statement and data-to-clinic summary

The rationale and evidence for PD-1 checkpoint inhibition in advanced CSCC

Which patients will likely benefit most? And when should we initiate treatment with PD-1-centric immunotherapy?

Todd E. Schlesinger, MD, FAAD – Program Chair
Director, Dermatology and Laser Center of Charleston | Clinical Research Center of the Carolinas | Clinical Instructor, University at Buffalo Department of Dermatology | Assistant Clinical Professor, Medical University of South Carolina Department of Family Medicine | Clinical Preceptor, Medical University of South Carolina College of Health Professions | Charleston, SC

**8:40 PM – 9:00 PM**
Interactive question and answer session

**EDUCATIONAL OBJECTIVES**

- Assess current NCCN and ASCO and AAD standards for diagnosing, staging, and treating advanced or metastatic CSCC
- Better understand the epidemiology, risk factors, and disease burden of advanced CSCC and the unmet need for better therapies to improve outcomes in the challenging population with advanced local spread and metastases
- Better understand the design, rationale, PFS, response rate, efficacy and side effects of PD-1 checkpoint inhibitors in the setting of CSCC and identify patients who can benefit from this form of immunotherapy
- Discuss and characterize the local stromal and immune-based microenvironment in CSCC and how immune-directed strategies may act to improve anti-tumor effects by maintaining and activating infiltrating T-cells
- Describe established and emerging checkpoint inhibitor therapies, including their novel mechanism of action, indications, timing of therapy, unique response patterns, and safety data in the setting of CSCC
- Identify when in the sequencing of chemotherapy and/or treatment with platinum-based regimens, patients with metastatic or advanced CSCC should be considered for treatment with emerging or established PD-1 checkpoint inhibitors to optimize clinical outcomes
- Discuss and analyze the trial design, results, and translational, front-line implications of Phase 1, 2, and/or 3 clinical trials evaluate the safety and efficacy of PD-1 checkpoint inhibitors in patients with PD-1 checkpoint inhibitors

**TARGET AUDIENCE—WHO SHOULD ATTEND?**

This Clinical Excellence Summit is directed at the following clinical specialists and providers: dermatologists, dermatologic oncologists, Mohs and head and neck surgical oncologists, dermatology nurses and nurse practitioners, and related healthcare providers who manage advanced skin cancer patients.

**AMERICANS WITH DISABILITIES ACT**

Event staff will be glad to assist you with any special needs (ie. physical, dietary, etc). Please contact CME Education Resources, LLC prior to the live event at (866) 912-4726.

**EDUCATIONAL SUPPORT**

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

**8:40 PM – 9:00 PM**
Interactive question and answer session

**Enrollment & Registration**

4 Ways to REGISTER NOW!

Enrollment for this course is complimentary. Register Now!

**REGISTER NOW ON-LINE:**

[www.reg-CSCC.com](http://www.reg-CSCC.com)

Please call to register:

1-888-977-1625

Fax us:

1-678-802-2813

Email us:

info@cmeducation.net

**Save the Time and Date:**

Friday, March 1, 2019

**Time:** 6:30 PM – 9:00 PM

**Location:** Marriott Marquis Washington DC | CONFERENCE ROOM: Liberty Ballroom M/N/O/P | ADDRESS: 901 Massachusetts Avenue NW

**Enrollment for this course is complimentary. Register Now!**